2024-512967-29-00已完成2 期
PaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Trial with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults with Hypoparathyroidism
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 21
- 试验地点
- 7
- 主要终点
- At 4 weeks of treatment, the proportion of subjects with: • Albumin-adjusted sCa within the normal range and • Spot morning fractional excretion of calcium (spot AM FECa) within normal range (≤2%) or a reduction by at least 50% from baseline and • Not taking active vitamin D supplements and • Taking ≤1000 mg/day of calcium supplements
研究概览
简要总结
To assess the effectiveness of daily TransCon PTH on serum and urine calcium levels (FECa) and active vitamin D and calcium doses at 4 weeks of treatment
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Males and females aged ≥18 years
- •Able to perform daily subcutaneous self-injections of study drug (or have a designee perform injection) via a pre-filled injection pen
- •Written, signed, informed consent of the subject
- •Subjects with postsurgical chronic HP or auto-immune, genetic, or idiopathic HP for at least 26 weeks. Diagnosis of HP is established based on hypocalcemia in the setting of inappropriately low serum parathyroid hormone (PTH) levels.
- •On a stable dose* for at least 12 weeks (US only: or 4 weeks if on Natpara as of September 2019) prior to Screening of: − ≥0.25 µg BID of calcitriol (active vitamin D) or ≥0.5 µg BID or ≥1.0 µg daily of alfacalcidol (active vitamin D) and − ≥400 mg BID calcium citrate or carbonate − If subject has a history of hypercalcemia on such doses, subject may be taking <0.25 µg BID of calcitriol, <0.5 µg BID or < 1.0 µg daily of alfacalcidol, or <400 mg BID of calcium citrate or carbonate, with approval of Medical Monitor/Medical Expert *Does not preclude occasional (<3/week) rescue doses of active vitamin D and/or calcium for symptomatic hypocalcemia
- •Optimization of supplements prior to randomization to achieve the target levels of: − 25(OH) vitamin D levels of 30-70 ng/mL (75-175 pmol/mL) and − Magnesium level within the normal range* and − Albumin-adjusted or ionized serum calcium (sCa) level in the lower half of the normal range *If subject has a history of inability to be successfully managed within the normal range for magnesium level, a level slightly below the normal range is acceptable with approval of the Medical Monitor/Medical Expert
- •BMI 17-40 kg/m2 at Visit 1
- •If ≤25 years of age, radiological evidence of epiphyseal closure based on x-ray of non-dominant wrist and hand
- •eGFR >30 mL/min/1.73m2 during Screening
- •Thyroid-stimulating hormone (TSH) within normal laboratory limits within the 12 weeks prior to Visit 1; if on suppressive therapy for thyroid cancer, TSH level must be ≥0.2 µIU/mL
- •If treated with thyroid hormone replacement therapy, the dose must be stable for at least 12 weeks prior to Visit 1
排除标准
- •Known activating mutation in the calcium-sensing receptor (CaSR) gene
- •Increased risk for osteosarcoma, such as those with Paget's disease of bone or unexplained elevations of alkaline phosphatase, open epiphyses, hereditary disorders predisposing to osteosarcoma, or with a prior history of substantial external beam or implant radiation therapy involving the skeleton
- •Pregnant or lactating women. NOTE: Highly effective contraception is required for sexually active women of childbearing potential during the trial and for 2 weeks after the last dose of study drug, and pregnancy testing will be performed throughout the trial. Sexually active women of childbearing potential who are unwilling to use highly effective contraception are excluded from the trial.
- •Diagnosis of drug or alcohol dependence within 3 years prior to Visit 1
- •Disease processes that may adversely affect gastrointestinal absorption including but not limited to short bowel syndrome, bowel resection, gastric bypass, tropical sprue, active celiac disease, active ulcerative colitis, gastroparesis, AIRE gene mutations with malabsorption, and active Crohn’s disease
- •Chronic or severe cardiac disease within 26 weeks prior to Visit 1 including but not limited to congestive heart failure, myocardial infarction, QTcF >430 msec (males) or >450 msec (females), severe or uncontrolled arrhythmias, bradycardia (resting heart rate <50 beats/minute), symptomatic hypotension, systolic BP <80 mm Hg or diastolic <40 mm Hg, or poorly controlled hypertension (systolic BP >150 mm Hg or diastolic >95 mm Hg)
- •Cerebrovascular accident within 5 years prior to Visit 1
- •History of renal colic or acute gout within 52 weeks prior to Visit 1
- •Any disease or condition that, in the opinion of the investigator, may make the subject unlikely to fully complete the trial, or any condition that presents undue risk from the investigational product or procedures, including treated malignancies that are likely to recur within the approximate 1-year duration of the trial
- •Known allergy or sensitivity to PTH or any of the excipients [metacresol, mannitol, succinic acid, NaOH/(HCl)]
- •Participation in another clinical trial in which receipt of investigational drug or device occurred within 8 weeks (or at least 5.5 times the half-life of the investigational drug) prior to Visit 1
- •Impaired responsiveness to PTH (pseudohypoparathyroidism) which is characterized as PTH-resistance, with elevated PTH levels in the setting of hypocalcemia
- •Likely to be non-compliant with respect to trial conduct
- •Any other reason that in the opinion of the investigator would prevent the subject from completing participation or following the trial schedule
- •Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than HP, such as active hyperthyroidism; Paget’s disease; hypomagnesemia; type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus; severe and chronic cardiac, liver, or renal disease; Cushing syndrome; rheumatoid arthritis; multiple myeloma; active pancreatitis; malnutrition; rickets; recent prolonged immobility; active malignancy (other than low-risk well differentiated thyroid cancer or basal cell skin cancer); parathyroid carcinoma within 5 years prior to Screening; acromegaly; multiple endocrine neoplasia types 1 and 2
- •Use of loop diuretics, phosphate binders (other than calcium carbonate/calcium citrate), digoxin, lithium, methotrexate, or systemic corticosteroids (other than replacement therapy)
- •Use of thiazide diuretic within 4 weeks prior to the Screening 24-hour urine collection or the first dose adjustment of SOC during Screening
- •Use of PTH-like drugs (whether commercially available or through participation in an investigational trial) including PTH(1-84), PTH(1-34), or other N-terminal fragments or analogs of PTH or PTH-related protein within 12 weeks (US only: 5 weeks) prior to Visit 1
- •Use of other drugs known to influence calcium and bone metabolism, such as calcitonin, fluoride tablets (> 0.5 mg/day), strontium, or cinacalcet hydrochloride within 12 weeks prior to Visit 1
- •Use of bisphosphonates (oral or IV) or denosumab within 2 years prior to Visit 1
- •Non-hypocalcemic seizure disorder with a history of a seizure within 26 weeks prior to Visit 1 NOTE: History of seizures that occur in the setting of hypocalcemia is not exclusionary
结局指标
主要结局
At 4 weeks of treatment, the proportion of subjects with: • Albumin-adjusted sCa within the normal range and • Spot morning fractional excretion of calcium (spot AM FECa) within normal range (≤2%) or a reduction by at least 50% from baseline and • Not taking active vitamin D supplements and • Taking ≤1000 mg/day of calcium supplements
At 4 weeks of treatment, the proportion of subjects with: • Albumin-adjusted sCa within the normal range and • Spot morning fractional excretion of calcium (spot AM FECa) within normal range (≤2%) or a reduction by at least 50% from baseline and • Not taking active vitamin D supplements and • Taking ≤1000 mg/day of calcium supplements
次要结局
- Key Secondary Efficacy Endpoint: At 4 weeks of treatment, the proportion of subjects with: • Albumin-adjusted sCa within the normal range and • FECa within the normal range or a reduction by at least 50% from baseline and • Not taking active vitamin D supplements and • Taking ≤500 mg/day of calcium supplements
研究者
Clinical Trial Information Desk
Scientific
Ascendis Pharma Bone Diseases A/S
研究点 (7)
Loading locations...
相似试验
尚未招募
2 期
Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's DiseaseParkinson DiseaseNCT07280299Gain Therapeutics, Inc.111
招募中
3 期
A Long-term Study of TS-172 in Hyperphosphatemia Patients on HemodialysisNCT07285304Taisho Pharmaceutical Co., Ltd.300
招募中
2 期
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationNCT07286292Institut de Recherches Internationales Servier (I.R.I.S.)10
招募中
3 期
A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCANCT07282353Cascade Pharmaceuticals, Inc135
已完成
1 期
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.NCT07272629Sanofi48